TICKERNERD
Menu
CGEMCGEMHealthcare · Biotechnology

CGEM Stock Forecast: Cullinan Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$15
−1.09% on the day

The 12 Wall Street analysts covering Cullinan Therapeutics, Inc. hold a median 12-month price target of $35 — +126.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$950.1M
Ticker Nerd rank
67 / 100
Median analyst target
$35
Analysts covering
12
Revenue$0.0
Operating income−$57.3M
Net income−$53.7M
Free cash flow−$38.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.4%
1M
−28.7%
YTD
+49.4%
1Y
+139.7%
From 52W high
−32.6%
From 52W low
+139.7%
$6
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CGEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cullinan Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Momentum
81
Value
75
Volatility
72
Growth
63
Quality
52
Size
45
Revisions
40
Issuance
31

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CGEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CGEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26CGEMHigh $42Median $35Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $23Median $35High $42

The green dot is the last close — the median target sits +126.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$35
25 Sept 2026BTIGReiteratesBuy$40
25 Sept 2026HC Wainwright & Co.MaintainsBuy$30 → $35
14 Sept 2026BTIGMaintainsBuy—
14 Sept 2026BTIGMaintainsBuy$39 → $40
17 Aug 2026HC Wainwright & Co.ReiteratesBuy$30
17 Aug 2026HC Wainwright & Co.ReiteratesBuy—
13 Aug 2026WedbushMaintainsOutperform—
13 Aug 2026WedbushMaintainsOutperform$39 → $42
29 July 2026BTIGMaintainsBuy—
29 July 2026BTIGMaintainsBuy$38 → $39
11 June 2026WedbushReiteratesOutperform$37
11 June 2026WedbushReiteratesOutperform—
8 June 2026HC Wainwright & Co.ReiteratesBuy$30
8 June 2026HC Wainwright & Co.ReiteratesBuy—
19 May 2026BTIGReiteratesBuy—
8 May 2026WedbushMaintainsOutperform—
4 May 2026BTIGReiteratesBuy—
28 Apr 2026BTIGReiteratesBuy—
28 Apr 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CGEM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CGEM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Cullinan Therapeutics, Inc. returned +139.7% against +16.2% for the S&P 500, dividends included.

CGEM vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26CGEMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CGEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
7
Fundamentals

Cullinan Therapeutics, Inc. (CGEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
9.0×

Cheaper than 60% of US stocks

Price / sales
—
Price / book
3.1×

Cheaper than 31% of US stocks

EV / EBITDA
−3.0×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.3%

Higher than 21% of US stocks

Return on assets
−31.4%

Higher than 13% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cullinan Therapeutics, Inc. (CGEM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cullinan Therapeutics, Inc. has a market value of $950.1M and an enterprise value of $662.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$204.7M.

  • Diluted earnings per share, trailing twelve months: $−3.10.

  • Free cash flow in the twelve months to 30 June 2026: −$159.3M.

  • Shares outstanding: 64.3M.

  • Trailing P/E: 9.0×; forward P/E: −6.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Cullinan Therapeutics, Inc. employs 109 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

CGEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CGEMCullinan Therapeutics, Inc.$950.1M
67
SVRASavara, Inc.$949.9M
33
SPTXSeaport Therapeutics, Inc.$949.7M
1
LTGOLatigo Biotherapeutics, Inc.$935.3M
1
ANROAlto Neuroscience, Inc.$934.1M
59
KURAKura Oncology, Inc.$933.8M
80
MGTXMeiragtx Holdings plc$971.9M
83

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cullinan Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CGEM news & analysis

Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia

GlobeNewsWire · 8 Oct 2026positive

Cullinan Therapeutics announced that the first patient has been dosed in its planned pivotal Phase 2 study of investigational FLT3 T cell engager CLN-049 for relapsed/refractory acute myeloid leukemia.

Why it matters — The study's first patient dosing marks the start of a pivotal clinical study for a Cullinan cancer candidate.

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

GlobeNewsWire · 1 Oct 2026positive

Cullinan Therapeutics has initiated a New Drug Application submission for zipalertinib in combination with chemotherapy for first-line treatment of EGFR exon 20 insertion mutation NSCLC, under the FDA's Real-Time Oncology Review program. The submission follows results from the Phase 3 REZILIENT3 study, which showed the longest median progression-free survival observed to date in this setting.

Why it matters — For CGEM watchers, this marks a key regulatory milestone as the company advances zipalertinib toward potential FDA approval in a first-line NSCLC setting where it reported leading progression-free survival data.

Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune Diseases

Seeking Alpha · 29 Sept 2026positive

Seeking Alpha discusses Cullinan Therapeutics' recent share-price pullback as a potential entry point ahead of clinical updates for its autoimmune pipeline, with CGEM scheduling updates for December 2026. The article notes that combined CLN-978 results could corroborate earlier data and that repeat dosing could support better efficacy if the therapy proves viable for more patients with a manageable safety profile.

Why it matters — A CGEM watcher would care because the article highlights upcoming clinical data for the CLN-978 autoimmune program that could validate earlier findings and broaden the therapy's patient potential.

Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049

MarketBeat · 28 Sept 2026neutral

Cullinan Therapeutics outlined upcoming clinical milestones across its immunology and oncology pipeline, including a planned December data update for its CD19-directed T-cell engager CLN-978 and data presentations for other programs in November and the fourth quarter. The company shared these planned catalysts without releasing results.

Why it matters — CGEM watchers would care because the scheduled data updates for CLN-978 and other pipeline programs represent near-term catalysts that could inform the company's clinical progress.

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

GlobeNewsWire · 24 Sept 2026neutral

Cullinan Therapeutics outlined fourth quarter 2026 milestones across its immunology and oncology T cell engager portfolio. Planned data presentations include velinotamig multi-dose regimen data in SLE at ACR Convergence 2026 in November, CLN-978 data in SLE, RA and Sjögren's disease in December, and updated CLN-049 Phase 1 dose escalation data in December.

Why it matters — These announced clinical data milestones give Cullinan Therapeutics watchers a timeline for potential readouts across its pipeline in the fourth quarter of 2026.

FAQ

Frequently asked questions about CGEM stock

What is the CGEM stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Cullinan Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $23 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CGEM stock a buy right now?

Of the 12 analysts covering Cullinan Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cullinan Therapeutics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CGEM?

As at 8 Oct 2026, Cullinan Therapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

Will CGEM stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +126.4% from the last close, and Ticker Nerd's factor model ranks Cullinan Therapeutics, Inc. 67 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CGEM stock forecast for 2030?

No analyst covering Cullinan Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CGEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $42 over the next 12 months.

How has CGEM stock performed over the past year?

Cullinan Therapeutics, Inc. returned +139.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cullinan Therapeutics, Inc. do?

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer.

What is the latest news on CGEM?

The most recent item we track (GlobeNewsWire, 8 Oct 2026): "Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia". Cullinan Therapeutics announced that the first patient has been dosed in its planned pivotal Phase 2 study of investigational FLT3 T cell engager CLN-049 for relapsed/refractory acute myeloid leukemia.

Company

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The company builds its pipeline around targeted and immune-based approaches, including T cell engagers, bispecific antibodies, monoclonal antibodies, and small-molecule candidates. Its current programs address a range of serious conditions across oncology and immunology, such as non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, systemic lupus erythematosus, and rheumatoid arthritis. Cullinan Therapeutics works to advance differentiated drug candidates through early- and mid-stage clinical development, with a business model centered on discovering high-impact molecules and moving them toward proof of concept. Based in Cambridge, Massachusetts, Cullinan Therapeutics plays a role in the biotechnology market as a developer of precision therapies for diseases with significant unmet medical need.

CEO Mr. Nadim Ahmed M.S. · 109 employees · United States · https://cullinantherapeutics.com